Provided by Tiger Fintech (Singapore) Pte. Ltd.

Krystal Biotech Inc.

138.48
+1.681.23%
Volume:334.67K
Turnover:46.14M
Market Cap:4.00B
PE:33.32
High:141.37
Open:136.32
Low:132.48
Close:136.80
Loading ...

Krystal Biotech early lung cancer data ‘promising,’ says H.C. Wainwright

TIPRANKS
·
19 Dec 2024

Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

MT Newswires Live
·
18 Dec 2024

BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

Reuters
·
18 Dec 2024

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
18 Dec 2024

Krystal Biotech Inc - Reports 27% Orr and 73% Dcr in Nsclc Trial

THOMSON REUTERS
·
18 Dec 2024

Krystal: Majority of Treatment-Related Adverse Events Been Mild to Moderate in Severity & Transient, With No Grade 4 or 5 Adverse Events Observed

THOMSON REUTERS
·
18 Dec 2024

Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Dec 2024

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Zacks
·
14 Dec 2024

Krystal Biotech announces initial update for KB408, KB407

TipRanks
·
13 Dec 2024

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Zacks
·
13 Dec 2024

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of Aatd Patients and Increase in Lung Aat to Therapeutic Levels

THOMSON REUTERS
·
12 Dec 2024

Krystal Biotech Inc - KB408 and KB407 Safe and Well Tolerated in All Doses

THOMSON REUTERS
·
12 Dec 2024

Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

BRIEF-Krystal Biotech Provides Update On EMA’S Ongoing Regulatory Review

Reuters
·
10 Dec 2024

Krystal Biotech Inc: Chmp Opinion NOW Expected in 1Q 2025

THOMSON REUTERS
·
10 Dec 2024

Krystal Biotech Provides Update on Ema’s Ongoing Regulatory Review of B-Vec for Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
10 Dec 2024

Krystal Biotech Inc: No Major Objections Outstanding; Continue to Expect Germany Launch in 2Q 2025

THOMSON REUTERS
·
10 Dec 2024

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

Zacks
·
06 Dec 2024

Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?

Zacks
·
05 Dec 2024

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks
·
29 Nov 2024